Point72 Asset Management
MRTX

Point72 Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Point72 Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-258,563
Closed -$11.3M – 3000
2023
Q3 		$11.3M Buy
+258,563
New +$9.23M 0.03% 606
2023
Q2 		– Sell
-645,500
Closed -$24M – 2928
2023
Q1 		$24M Sell
645,500
-108,100
-14% -$4.86M 0.07% 300
2022
Q4 		$34.1M Buy
753,600
+651,753
+640% +$42.2M 0.12% 228
2022
Q3 		$7.11M Sell
101,847
-8,753
-8% -$648K 0.03% 614
2022
Q2 		$7.42M Buy
+110,600
New +$7.03M 0.03% 600
2022
Q1 		– Sell
-479,845
Closed -$70.4M – 1445
2021
Q4 		$70.4M Buy
+479,845
New +$74.5M 0.28% 74
2021
Q3 		– Sell
-40,000
Closed -$6.46M – 1282
2021
Q2 		$6.46M Sell
40,000
-227,400
-85% -$36.5M 0.03% 549
2021
Q1 		$45.8M Buy
267,400
+51,937
+24% +$10.3M 0.21% 121
2020
Q4 		$47.3M Buy
+215,463
New +$46.6M 0.23% 103
2020
Q3 		– Sell
-186,721
Closed -$21.3M – 1139
2020
Q2 		$21.3M Buy
+186,721
New +$18.1M 0.14% 208
2019
Q4 		– Sell
-596,169
Closed -$46.4M – 1322
2019
Q3 		$46.4M Buy
596,169
+187,234
+46% +$17.6M 0.29% 103
2019
Q2 		$42.1M Buy
408,935
+391,735
+2,278% +$30.5M 0.22% 119
2019
Q1 		$1.26M Buy
+17,200
New +$1.17M 0.01% 777
2018
Q4 		– Sell
-15,500
Closed -$730K – 1282
2018
Q3 		$730K Buy
+15,500
New +$863K ﹤0.01% 889
2018
Q2 		– Sell
-407,929
Closed -$12.5M – 1232
2018
Q1 		$12.5M Buy
407,929
+327,030
+404% +$9.08M 0.05% 378
2017
Q4 		$1.48M Buy
+80,899
New +$1.26M 0.01% 770

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Point72 Asset Management's MRTX Position: Q4 2023 in Review

Point72 Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 258,563 shares — an estimated $11.3M sold.

Point72 Asset Management first reported a position in MRTX in Q4 2017 and held it in 16 quarters. The position peaked at $70.4M in Q4 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Point72 Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Point72 Asset Management sold 258,563 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $11.3M.
  • Point72 Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2017 and held it in 16 quarters.
  • Point72 Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $70.4M in Q4 2021.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.